Literature DB >> 583025

The interaction of adriamycin with small unilamellar vesicle liposomes. A fluorescence study.

G S Karczmar, T R Tritton.   

Abstract

The interaction of the antineoplastic agent adriamycin with sonicated liposomes composed of phosphatidylcholine alone and with small amounts (1-6%) of cardiolipin has been studied by fluorescence techniques. Equilibrium binding data show that the presence of cardiolipin increases the amount of drug bound to liposomes when the bilayer is below its phase transition temperature and when the ionic strength is relatively low (0.01 M). At higher ionic strength (0.15 M) and above the Tm (i.e. conditions which are closer to the physiological state) the binding of the drug to the two liposome types is nearly the same. Thus the differences in the interactions of adriamycin with cardiolipin-containing membranes, as opposed to those composed of phosphatidylcholine alone, are not due simply to increased binding but rather to an altered membrane structure when this lipid is present. Quenching of adriamycin fluorescence by iodide shows that bound drug is partially, but not completely, buried in the liposomal membrane. Both in the presence and absence of cardiolipin the bulk of the adriamycin is more accessible to the quencher below the Tm than above it; that is, a solid membrane tends to exclude the drug from deep penetration. Above the Tm, the presence of cardiolipin alters the nature of liposome-adriamycin interaction. Here the fluorescence quenching data suggest that the presence of small amounts of cardiolipin (3%) in a phosphatidylcholine matrix creates two types of binding environments for drug, one relatively exposed and the other more deeply buried in the membrane. The temperature dependence of the adriamycin fluorescence and the liposome light scattering reveal that cardiolipin alters the thermal properties of the bilayer as well as its interaction with adriamycin. At low ionic strength lateral phase separations may occur with both pure phosphatidylcholine and when 3% cardiolipin is present; under these conditions the bound adriamycin exists in two kinds of environment. It is notable that only adriamycin fluorescence reveals this phenomenon; thebulk property of liposome light scattering reports only on the overall membrane phase change. These data suggest that under certain conditions the drug binding sites in the membranes are decoupled from the bulk of the lipid bilayer.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 583025     DOI: 10.1016/0005-2736(79)90329-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group.

Authors:  T G Burke; A C Sartorelli; T R Tritton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Adriamycin inhibits PTH-mediated but not PGE2-mediated stimulation of cyclic AMP formation in isolated bone cells.

Authors:  G Kohler; V Shen; W A Peck
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

Review 3.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

4.  Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells.

Authors:  C A Carter; K W Bair
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

5.  Binding of adriamycin to liposomes as a probe for membrane lateral organization.

Authors:  T Söderlund; A Jutila; P K Kinnunen
Journal:  Biophys J       Date:  1999-02       Impact factor: 4.033

6.  Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells.

Authors:  W M Holleran; M W DeGregorio; R Ganapathi; J R Wilbur; B A Macher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Physical entrapment of adriamycin in AB block copolymer micelles.

Authors:  G S Kwon; M Naito; M Yokoyama; T Okano; Y Sakurai; K Kataoka
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.